PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-9.15%
Both yoy net incomes decline, with CRON.TO at -82.42%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
0.26%
Less D&A growth vs. CRON.TO's 12.48%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
101.23%
Deferred tax of 101.23% while CRON.TO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-4.62%
Both cut yoy SBC, with CRON.TO at -4.53%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-282.36%
Both reduce yoy usage, with CRON.TO at -342.93%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
80.67%
AR growth while CRON.TO is negative at -203.87%. John Neff would note competitor possibly improving working capital while we allow AR to rise.
-14.58%
Both reduce yoy inventory, with CRON.TO at -739.61%. Martin Whitman would find a widespread caution or cyclical demand drop in the niche.
-127.09%
Both negative yoy AP, with CRON.TO at -199.03%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-214.91%
Both reduce yoy usage, with CRON.TO at -588.73%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-103.09%
Negative yoy while CRON.TO is 99.55%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-213.44%
Both yoy CFO lines are negative, with CRON.TO at -127.15%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
28.46%
Some CapEx rise while CRON.TO is negative at -330.65%. John Neff would see competitor possibly building capacity while we hold back expansions.
-100.00%
Negative yoy acquisition while CRON.TO stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-251.99%
Negative yoy purchasing while CRON.TO stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
-100.00%
We reduce yoy sales while CRON.TO is 100.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-99.97%
We reduce yoy other investing while CRON.TO is 30.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-212.85%
Both yoy lines negative, with CRON.TO at -1000.08%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-989.09%
We cut debt repayment yoy while CRON.TO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
671.23%
Issuance growth of 671.23% while CRON.TO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.